Epsilon Group Launches FDA-Approved Type 1 Diabetes Simulator | GenomeWeb

By Uduak Grace Thomas

The Epsilon Group, a Charlottesville, Va.-based medical research firm, has launched the Type 1 Diabetes Metabolic Simulator, or T1DMS, an in silico diabetes simulator based on technology licensed from the University of Virginia.

According to the company and UVA, the simulator is the first in silico tool to receive the US Food and Drug Administration's approval as a substitute for preclinical animal testing of type 1 diabetes control strategies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.